2011年7月至2019年8月美国军人接种Vero细胞培养日本脑炎疫苗与Vi荚膜多糖伤寒疫苗后特定不良事件发生频率比较
回顾性比较2011年7月1日至2019年8月31日美军人员单独接种Vero细胞培养日本脑炎疫苗(JE-VC)或Vi荚膜多糖伤寒疫苗后28天内超敏反应和神经系统不良事件发生率。多数事件发生率相似,仅迟发型超敏反应在JE-VC后更频繁(率比4.2,95%CI 1.2-15.3;p=0.03),但两种疫苗发生率均低。结果支持JE-VC的安全性。
要点
- 多数超敏和神经系统不良事件发生率在JE-VC与Vi伤寒疫苗间相似。
- 仅迟发型超敏反应在JE-VC后更频繁(率比4.2,95%CI 1.2-15.3;p=0.03)。
- 两种疫苗的迟发型超敏反应发生率均低,结果支持JE-VC安全性。
核心结论
- 研究结果支持Vero细胞培养日本脑炎疫苗的安全性。
研究设计与样本
- 回顾性比较2011年7月1日至2019年8月31日美军人员接种JE-VC或Vi荚膜多糖伤寒疫苗(未同时接种其他疫苗)后28天内超敏反应和神经系统不良事件发生率。
主要发现
- 多数事件发生率在两种疫苗间相似。
- 仅迟发型超敏反应在JE-VC后更频繁(率比4.2,95%CI 1.2-15.3;p=0.03),但两种疫苗发生率均低。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Vero cell culture-derived Japanese encephalitis (JE) vaccine (JE-VC; Ixiaro) was approved in the United States in 2009. The previous JE vaccine, an inactivated mouse brain-derived vaccine, had been associated with rare, but serious, allergic and neurologic adverse events (AE). Studies and AE surveillance have supported JE-VC's safety, but one evaluation among military personnel found elevated hypersensitivity and neurologic AE rates. However, co-administration of multiple vaccines to some personnel might have affected results. We retrospectively compared rates of hypersensitivity and neurologic AEs within 28 days following vaccination of military personnel with JE-VC or parenteral Vi capsular polysaccharide typhoid vaccine administered without other vaccines from July 1, 2011, through August 31, 2019. Rates of most events were similar between the vaccines. Only delayed hypersensitivity reactions occurred more frequently following JE-VC (rate ratio: 4.2, 95 % CI 1.2-15.3; p = 0.03), but rates were low for both vaccines. These results support JE-VC's safety.
引用
- Seshadri S, Martin SW, Hills SL, et al. Comparative frequency of specified adverse events following Vero cell culture-derived Japanese encephalitis and Vi capsular polysaccharide typhoid vaccines in U.S. military personnel, July 2011-August 2019. Vaccine. 2023. PMID: 36725428. doi:10.1016/j.vaccine.2023.01.061
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。